Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 338

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 338
---
-26 |
| Consolidated statements of changes in equity for the years ended 31 December 2023, 2022 and 2021    | F-28 |
| Notes forming part of the consolidated financial statements                                         | F-31 |

| 173 |

Consolidated Statements of Comprehensive Income

For the year six month period ended June 30

|                                                                   |     | Note |     | 2024 unaudited £’000 |    |     | 2023 unaudited £’000 |    |
| Revenue                                                           |     |      |     |                    - |    |     |                  298 |    |
| Research and development costs                                    |     |      |     |               (2,189 | )  |     |               (2,251 | )  |
| Administrative costs                                              |     |      |     |               (2,034 | )  |     |               (2,291 | )  |
| Loss from operations                                              |     |      |     |               (4,223 | )  |     |               (4,244 | )  |
| Finance income                                                    |     |    3 |     |                  839 |    |     |                  410 |    |
| Finance expense                                                   |     |    3 |     |                  (49 | )  |     |                  (22 | )  |
| Loss before tax                                                   |     |      |     |               (3,433 | )  |     |               (3,856 | )  |
| Taxation                                                          |     |    4 |     |                  125 |    |     |                  288 |    |
| Loss for the period attributable to the owners of the parent      |     |      |     |               (3,308 | )  |     |               (3,568 | )  |
| Total comprehensive loss attributable to the owners of the parent |     |      |     |               (3,308 | )  |     |               (3,568 | )  |
| Loss per share                                                    |     |      |     |                      |    |     |                      |    |
| Basic and diluted loss per ordinary share – pence                 |     |    5 |     |                 (0.1 | p) |     |                 (3.6 | )p |

The accompanying notes
form part of these financial statements

| F-1 |

Consolidated Statements of Financial Position

|                                                                  |     |